Recently, the biosimilar Adalimumab (Taibowei^®) from Chia Tai Tianqing, a member company of Sino Biopharm (1177.HK), was officially approved for marketing by the Algerian Medicines Agency. This will bring a high-quality and affordable new treatment option to patients with autoimmune disorders in countries participating in the "Belt and Road" initiative. Adalimumab is a fully human anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, a key drug for treating various autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

Excellent Quality Enhances Accessibility of Clinical Treatment

The core of biosimilar R&D lies in demonstrating a high degree of similarity to the innovator reference drug in terms of quality, safety, and efficacy. Since 2015, the National Medical Products Administration (NMPA) of China has been progressively improving the approval system for biosimilars, requiring head-to-head clinical equivalence trials and continuous post-marketing surveillance after approval. As of 2024, China has approved more than 20 biosimilars, and the marketing approval of Taibowei® is one of the successful examples.

Drug quality management is not only crucial for patients' lives and health but is also the "lifeline" of a company's development. Chia Tai Tianqing has large-scale R&D and production bases in Nanjing and Lianyungang, Jiangsu, with multiple production lines having passed EU cGMP and US FDA certifications. Among them, its subsidiary, Lianyungang Runzhong Pharmaceutical Co., Ltd., has passed US FDA on-site inspections three times with excellent "zero-deficiency" performance. First-class quality management has become the company's "golden key" to develop international markets.

Deepening "Belt and Road" Cooperation in the Pharmaceutical Sector

Algeria, located in northwestern Africa, is the largest country in Africa and one of the important pharmaceutical markets in the North Africa region. As a country participating in the "Belt and Road" initiative, Algeria has seen rapid growth in healthcare demand in recent years, with an urgent need for high-quality and affordable biologic drugs. Algeria is an important milestone for the company's overseas expansion of biologic drugs. The company will work closely with local partners to accelerate the product's commercialization process and ensure timely patient access.

This successful approval is not only a significant achievement of the company's integration into the global pharmaceutical industry chain and its proactive engagement with the national "Belt and Road" initiative, but also the inevitable result of the company's long-term commitment to comprehensive innovation and internationalization strategies. In the field of biologic drugs, the company has a well-established technology platform. Several biosimilars such as Bevacizumab, Rituximab, and Trastuzumab, as well as the Class 1 innovative drug Benmelstobart, have all been approved for marketing in China, accumulating a rich product portfolio for future international expansion.

In the future, the company will continue to leverage innovation as its engine, deepen further cooperation with overseas partners, and focus on meeting the clinical needs of countries participating in "Belt and Road". It will export high-quality and affordable drugs to contribute to the construction of the "Health Silk Road".

Disclaimer:

1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes.

2. The company does not recommend any drugs and/or indications.

3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific information about disease diagnosis and treatment, please follow the advice or guidance of a doctor or other healthcare professional.